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Abstract
Background: Metformin associated lactic acidosis (MALA) is a well-known serious side effect of biguanides. However,
the best treatment strategy remains a matter of debate. In the last 14 years, we observed a significant increase in
hospitalizations for MALA to our Center. We report the outcomes of our clinical and therapeutic approach.
Methods: This is a single-center case series. Twenty-eight patients affected with MALA and acute kidney failure
admitted between January 2000 and September 2014 were included. We analyzed comorbidities, laboratory tests and
clinical parameters at admission, at 36 h and at discharge. All patients were treated with sustained low-efficiency
dialysis (SLED) until normalization of serum lactate (≤ 3 mmol/L), bicarbonate (between 20 and 25 mmol/L) and
potassium (between 4.0 and 5.1 mmol/L).
Results: The mortality rate was 21.4%, with all of the events occurring within 24 h from admission, and before or
during the first hemodialysis treatment. Precipitating causes included; acute dehydration (86.4%), systemic inflammatory
response syndrome (SIRS) (57.1%), sepsis (10.7%), nephrolithiasis (14.6%) and exposure to iodinated contrast (7.1%). No
further episodes of lactic acidosis were described after discontinuing the drug over a mean follow-up of 27.2 months.
Furthermore, while in 2010, we had a peak incidence of MALA of 76.8 cases per 100,000 patients on metformin, this rate
fell after an education campaign conducted by specialists on the proper usage of metformin in patients at risk of MALA.
Although the fall in incidence after the educational program was not necessarily causal, in 2014 the incidence was
32.9/100,000.
Conclusions: We report an improved mortality rate in patients affected with MALA and acute kidney injury treated with
SLED compared with other series published in literature. Rapid introduction of effective hemodialysis is critical in
improving outcomes.
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Background
Metformin is a first line drug therapy both to treat type
2 diabetes mellitus as well as prevent diabetic-related
complications [1–3]. It is widely considered safe and well
tolerated. Mechanistically, metformin counters insulin
resistance by enhancing the basal cellular uptake of
glucose, and by blocking the precursors of gluconeogene-
sis in the liver. Clinical research demonstrated that met-
formin reduces postprandial glycemia by 20-30% and, as
demonstrated in the United Kingdom Prospective
Diabetes Study (UKPDS 34), can delay the onset of micro
and macrovascular disease [2, 4–6]. Moreover, it reduces
all-cause mortality (− 36%), as well as diabetes-related
complications (32%) and diabetes-related deaths (− 47%)
[7]. In addition, a number of pleiotropic effects have been
reported such as improvement of non-alcoholic steatohe-
patitis [8].
Despite these benefits, some at risk populations, in
particular patients with renal disease and low glomerular
filtration rates (GFR) (≤ 60 ml/min) can accumulate met-
formin in tissues leading to lactic acidosis, which can be
life threating [9]. This phenomenon is explained through
in vitro and in vivo observations: metformin reduces oxi-
dative phosphorylation, increasing serum lactate levels if
drug concentrations rise excessively [10, 11]. The magni-
tude of metformin associated lactic acidosis (MALA) is
matter of debate; in controlled studies, it is diagnosed in
4.3 per 100,000 patient-years [12]. However, several case
series described a much higher incidence that likely is
more reflective of the “real world” situation [13].
Metformin associated lactic acidosis (MALA) is defined
as a lactic acidosis in a patient with documented regular
intake of metformin as well as comorbid conditions that
increase the risk of lactic acidosis such as heart failure
and kidney disease [14].
Over the last fourteen years we had observed a consid-
erable annual incidence of MALA in the setting of acute
kidney injury (AKI) or acute on chronic kidney disease
(AoCKD) at our Center. MALA often occurred in pa-
tients with an exacerbation of comorbid conditions. In
order to better understand the etiology and outcomes of
MALA, we reviewed a case series of patients who were
admitted to our Center with a diagnosis of MALA and
AKI. The main aim of our analysis was to evaluate the
efficacy of our clinical and therapeutic approach as com-
pared with the reported outcomes in the literature in
terms of overall survival in the short (7 days) and long
term (last follow-up or phone interview).
Methods
This is a retrospective, single center, case series of MALA
and AKI. The Division of Nephrology and Dialysis of the
Azienda Ospedaliera G. Brotzu, Cagliari, Italy, cared for
all cases. Patients included in the analysis: type 2 diabetes
mellitus diagnosed at least one year earlier; metformin use
as monotherapy or concomitant with other anti-diabetic
medications before the development of lactic acidosis;
acute kidney failure (AKI stage III) according with KDIGO
Clinical Practice Guideline for Acute Kidney Injury [15];
metabolic acidosis as defined by the reduction of serum pH
(≤ 7.34 [7:35-7.42]) and serum bicarbonate (≤ 22 mmol/L
[22–26]); and lactic acidosis (metabolic acidosis with an in-
creased anion gap and lactate concentration ≥ 5 mmol/L).
Those patients not meeting the above listed criteria were
excluded from analysis.
We identified 28 patients with a diagnosis of MALA
and AKI who were admitted to our Division between
January 2000 and September 2014 (Table 1). Protocol.
Metformin was discontinued in the identified patients
and treatment for diabetes was initiated with insulin
and/or a low carbohydrate diet. In all cases, patients
were treated with a sustained low-efficiency dialysis
(SLED) using bicarbonate buffer. The goal of the treat-
ment was metabolic normalization, in particular lactate
(≤ 3 mmol/L), bicarbonate (between 20 and 25 mmol/L)
and potassium (between 4.0 and 5.1 mmol/L). A meta-
bolic panel was requested every 2 h during the treatment
to prevent overcorrections and ensure that goals were
being met, and every 12 h after the treatment. Of note,
severe hyperkalemia was gradually corrected to ensure
hemodynamic stability and avoid sudden drops of the
serum concentration of potassium. In particular, if
serum potassium was high (≥ 6.5 meq/l), we first cor-
rected it with a potassium concentration of 5 in the bath
and then subsequently lowered the potassium with less
concentrated solutions.
Patients did not receive sodium bicarbonate i.v. before
hemodialysis. Since there is little correlation between
serum metformin drug levels with outcomes, metformin
levels were not measured. Vital signs and laboratory
studies were recorded at admission, three days after ad-
mission, and at discharge.
Follow-up
After discharge, most of the 23 surviving patients were
followed at our outpatient clinic. After a mean of 27.2 ±
24.8 months from metformin discontinuation, we asked
survivors whether they experienced similar episodes in
the future, about their knowledge on the drug side ef-
fects before the event and if they resumed the intake of
the drug after the event.
Educational campaign
In 2010 we observed the peak of a progressive annual
rise in the incidence of MALA. This triggered us to
organize several dedicated courses on MALA for spe-
cialists and general practitioners, and specific sessions in
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local congresses held by diabetologists, internists and
nephrologists.
Laboratory parameters are expressed as mean and
standard deviation (SD) for normally distributed variables
and median and interquartile range for non-parametric
data. The evolution of lab exams at admission and after
3 days was reported and differences were assessed with
the paired t-test. Statistical analysis was carried out using
SPSS 22 (IBM Corporation, USA).
We defined systemic inflammatory response syndrome
(SIRS) and sepsis as recommended by ACCP/SCCM
(2012) [16].
Results
We identified 28 patients diagnosed with MALA from
our hospital records. There was a prevalence of males
(M:F 1.5:1), and the mean age was 66.7 ± 9.5 yrs. Clinical
and laboratory findings at admission were diagnostic for
AKI stage 2 in 3.6% and stage 3 in 96.4% of patients
(Table 1). However, after the first 24 h of observation, all
patients met criteria for AKI stage III. Notably, 50% of
MALA cases were observed in subjects with previously
normal kidney function, and in 25% of cases, MALA de-
veloped in subjects with previously diagnosed mild to
moderate chronic kidney disease (sCr 1.16 ± 0.48 mg/dl;
eGFR CKD-EPI 71.9 ± 26.5 ml/min/1.73 m2) (Table 2).
Comorbid conditions included: hypertension (71.4%),
neoplastic disease (17.9%), chronic obstructive pulmon-
ary disease (COPD) (7.1%) and heart failure (14.3%)
(Additional file 1: Table S1). We did not identify any
combination of comorbidities associated with an in-
creased risk for mortality. Our cohort was treated as fol-
lows: a mean of 6.9 ± 1.8 h of treatment were provided
with low blood fluxes (QB from 80 to 140 ml/min) due
to cardiovascular instability and mono-lumen catheters
that we use for an urgent dialysis; dialyzers were based
on multi-branded polysulfone membranes.
A limited number of causes in this patient cohort that
could worsen kidney function were identified. These in-
cluded pre-renal etiologies, volume depletion (85.7%)
secondary to nausea and vomiting (53.6% and 57.1%,
Table 1 Descriptive statistics of selected patients at admission.
M:F (male/female ratio); SD (standard deviation); CKD (chronic
kidney disease)
Demographics and baseline characteristics
Demographics
N° of patients 28
M:F 1.5: 1
Mean age ± SD 66.7 ± 9
% of ≥ 65 years 60.7
% of ≥ 80 years 3.5
Status on admission
N° days with symptoms ± SD before
the admission
6.04 ± 5
Days of admission 10.6 ± 6.7
Systolic Pressure (mmHg) 125 ± 32.3
Diastolic Pressure (mmHg) 64.6 ± 16
Body temperature (°C) 36.9 ± 0.8
% Oliguria 71.4
Renal function
Mean sCr (mg/dl) before the admission 1.16 ± 0.48
Mean eGFR CKD EPI (ml/min/1.73 m2) before
the admission
71.9 ± 26.5
AKI stage (%) Stage I – 0%
Stage II – 3.6%
Stage III – 96.4
CKD stage n (%) before the AKI Stage I - 14 (50)
Stage II - 7 (25)
Stage III - 7 (25)
Stage IV - 0 (0)
Stage V - 0 (0)
Comorbidities
% Heart Failure 14.2
% Iodinated contrast agent 3.5
% Moderate to severe anemia 35.7
% Vascular disease 21.4




% Hemodialysis post-admission 100
Number of hemodialysis sessions 2.26 ± 2
Table 2 Laboratory parameters at time 0 (admission) and at
36 h, intended as means and standard deviation (SD); EB (excess
of bases), pCO2 (CO2 partial blood pressure)
Laboratory parameters at time 0 (admission) and at 36 h, intended as
means and standard deviation (SD)
Variable (mean ± SD) Time 0 Time 1 (36 h) Sig.
Serum Creatinine (mg/dl) 8.1 ± 3.1 5.3 ± 2.8 p < 0.05
Blood Urea Nitrogen (mg/dl) 96.8 ± 47.4 54.6 ± 27.4 p < 0.05
Hemoglobin (g/dl) 10.7 ± 1.6 11.2 ± 1.8 p NS
Potassium (mEq/L) 5.93 ± 1.4 4.03 ± 0.8 p < 0.05
Glycemia (mg/dl) 178.8 ± 123 160.1 ± 24 p NS
C-reactive protein (mg/dl) 8.6 ± 8.9 4.3 ± 2.3 p < 0.05
pH, serum 7.01 ± 0.22 7.35 ± 0.7 p < 0.05
HCO3 -(mmol/L) 7.72 ± 4.4 22.7 ± 6.4 p < 0.05
EB (mmol/L) −19.3 ± 11.7 −1.92 ± 5.6 p < 0.05
Lactate (mmol/L) 13.7 ± 6 2.6 ± 2.6 p < 0.05
Anion gap (mmol/L) 36.2 ± 8.2 13.2 ± 4.1 p < 0.05
VpCO2 (mEq/L) 25.7 ± 9.5 39.1 ± 4.4 p < 0.05
VpO2 (mEq/L) 65.4 ± 10.5 42.4 ± 9.9 p < 0.05
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respectively). Nephrolithiasis caused post-renal acute
renal failure in 14.3% of patients. Systemic inflammatory
response syndrome (SIRS) was frequently diagnosed
(57.1%), and 10.7% of hospitalized patients had criteria
diagnostic of sepsis (E. coli was the most frequent patho-
gen (2/4 cases)). Two patients developed AKI after
administration of iodinated contrast medium, developing
MALA because metformin had not been discontinued.
Mild (10-12 g/dl) to moderate (8-9.9 g/dl) anemia often
concurred in this condition (37.5%).
Elevated levels of serum creatinine (mean: 8.1 ± 3.1 mg/dL)
and blood urea nitrogen (mean: 96.8 ± 47.4 mg/dL), as
well as hyperkalemia (mean: 5.93 ± 1.4 mEq/L), low pH
values (median: 7.01 ± 0.22) and elevated blood lactate
values (median: 13.7 ± 6 mEq/L) characterized patients at
admission. After their first emergency hemodialysis, 21.4%
of patients died. This occurred within the first 24 h of
admission (Fig. 1). Mean hospitalization length was
10.6 ± 6.7 days, and a mean of only 2.26 ± 2 hemodialytic
sessions (HD) were performed. Kidney function rapidly re-
covered in the surviving patients, and in some cases within
36 h. Metabolic parameters also normalized significantly
within the same time frame (pH [7.36 ± 0.072], HCO3-
[22.71 ± 6.44 mmol/L], lactate levels [2.6 ± 2.65 mmol/L]).
Patients who were oliguric at admission recovered urine
output within 36 h. At discharge, metabolic parameters
were still within normal range, but 14.8% of patients did
not recover to their previous values of renal function. We
did not observe any MILA, unlike occasionally reported in
the literature [17, 18].
These subjects were then followed-up as outpatients
for a mean of 27.2 months in order to assess changes in
kidney function and to document whether lactic acidosis
reappeared despite metformin discontinuation. Tele-
phone interviews allowed us to collect data from the
other patients cared for in other facilities. A brief
interview with the patients and their relatives revealed
that: 1) none of them knew how to recognize either the
initial symptoms of MALA or the signs and risks of
sudden decline in kidney function. Above all, none of
the patients knew when to discontinue metformin if they
developed an illness and therefore they all continued
taking the drug until admission to hospital; 2) after
discharge, 2 of 23 patients died from causes other than
lactic acidosis; 3) no new episodes of lactic acidosis were
reported; 4) the onset of symptoms that led to a diagno-
sis of MALA started a mean of 6 days before admission.
Considering that our operative area accounts for
552.303 inhabitants and that 1.55 individuals out of
every 100 have a prescription for metformin, we esti-
mated that in our district there are about 8560 patients
taking metformin. Thus, in 2010, we had a peak inci-
dence of MALA of 76.8 cases per 100,000 patients on
metformin, that fell after an education campaign con-
ducted by specialists on its usage in patients at risk of
MALA (Additional file 2: Figure S1). Although the fall
in incidence after the educational program is not neces-
sarily causal, in 2014 the incidence was 32.9/100,000,
while prescription rate remained almost stable in
this period.
Fig. 1 Kaplan-Meier survival curve of admitted-discharged patients affected with MALA (admission, time 0 – 25 days). Discharged patients are
marked as censored. During the follow-up (mean 27.2 months), none of the surviving patients experienced new episodes of lactic acidosis after
discontinuing the drug. Two patients died at follow-up for reasons other than lactic acidosis
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Discussion
Currently, type 2 diabetes is progressing at alarming
rates in Europe, US and Italy [19, 20]. Although there
are no official data regarding the incidence of T2D in
Sardinia, some regional reports show a growing ten-
dency, estimated at about 5000 new cases every year.
The number of affected subjects is estimated around
94,000 [20]. In Italy, antidiabetic drug use increased by
37% between 2000 and 2009 [3], especially oral anti-
diabetics (+ 22%). Prescriptions for metformin as the
initial treatment for incident cases of type 2 diabetes
increased exponentially, going from 8.3% in 1998 to
54.3% in 2010 [21]. The result of an increase in the
number of prescriptions is, of course, an increase in the
number of reported adverse events [22]. The most ser-
ious side effect of metformin is lactic acidosis, a form of
severe metabolic acidosis with a concomitant increase in
serum concentrations of lactate ≥ 5 mmol/L. This is the
result of blockade of pyruvate flow through its metabolic
pathway induced by high levels of metformin. Pyruvate
is the product of glucose metabolism through glycolysis
and subsequently enters into the mitochondrial Krebs
Cycle and oxidative phosphorylation. This blockade
leads to a significant decrease in ATP generation and an
increase in protons, resulting in a consequent reduction
of pH in the cytoplasmic fluid due to continuous ATP
hydrolysis [21]. This ultimately leads to a block in pyru-
vate metabolism and the excess pyruvate that cannot be
managed by the mitochondria is transformed into lac-
tate, especially within the liver, intestine and, to a lesser
extent, in other tissues [23, 24]. It is well known that
MALA often occurs as the consequence of an abrupt in-
crease in the concentration of metformin in tissues and
serum, often following a rapid decline in kidney function
and decrease in metformin excretion [25].
Although rare, MALA generated a great deal of con-
cern that delayed the introduction of metformin into the
US market until May, 1995 [26]. This was only after
extended studies and meta-analyses determined that the
condition was rare especially in those with normal
kidney function [22, 27]. A Cochrane meta-analysis
carried out by Salpeter et al. included reports published
between January, 1959 and October, 2009, and involved
70,490 patients who had taken metformin for at least
1 month [12]. The results showed an annual MALA
incidence of 4.3 cases per 100,000 patient-years in the
metformin group and 5.4 per 100,000 patient-years in
the non-metformin group, resulting in a paradoxical
protective effect of metformin against lactic acidosis due
to other causes. However, the work by Salpeter actually
estimated the incidence of MILA, a lactic acidosis gener-
ated by a metformin poisoning alone and known to be
quite uncommon, instead of MALA. In fact, it differs
significantly from the “real world” experience, where
several comorbidities able to generate lactic acidosis may
easily coexist in our patients.
Of note, many cases of MALA may have been pre-
vented before “the point of no return” by discontinuing
the drug at the onset of suspicious symptoms or when
patients developed conditions such as volume depletion
which would reduce GFR and increase metformin levels.
So far in 2014, the incidence of the phenomenon is half
what it was in 2010, but still high, as reported in other re-
cent papers [28]. Moreover, the National Pharmacovigilance
Network, a system for data collection and management of
suspected adverse reactions of the Italian Medicines
Agency, analyzed the cases of MALA reported only 59
new cases of MALA in the 10 year period November 2001
to October 2011, suggesting elevate rates of missed
reports [29].
Our patients were affected by comorbidities that may
themselves generate lactic acidosis independently of
metformin use. However, arguing against this is that
after discontinuing the drug, there were no further
events. In fact, MALA is currently the main etiology of
lactic acidosis among the patients in our ward. Mortality
was relatively low in our cohort (21.4%) and all deaths
occurred within 24 h of admission. A review of electro-
cardiographic data in these deaths revealed ventricular
tachycardia first, then followed by ventricular fibrillation.
The 24-h critical limit for mortality has also been re-
ported by other authors in the literature [27]. Mortality
was below 45% in a meta-analysis by Lalau et al., but
higher compared to our data [30]. Another report from
Seidowsky et al showed even a higher mortality inci-
dence of 48% [31].
The death events occurred during the first hemodialy-
tic treatment (after a mean of 3:15 h of treatment,
around 5 h since admission) or soon after (two patients
died 24 h since admission and one patient after 22 h).
Patients had very similar clinical presentations, com-
monly with moderate to severe dehydration associated
with vomiting, diarrhea and oliguria. Upon admission to
our Division, blood gases often showed high levels of
venous pO2, most likely because of hyperventilation sec-
ondary to severe acidosis and the exclusion of the Krebs
cycle from cellular metabolism due to metformin intoxi-
cation, in agreement with Protti et al [32].
We believe that the improved mortality seen in our
cohort is due to aggressive use of SLED along with more
gradual correction of metabolic derangements. Interest-
ingly, recent guidelines had been published by the
EXTRIP workgroup, that are much more conservative
compared with our approach. In fact, hemodialysis is
indicated if any of the following conditions (lactate con-
centration greater than 20 mmol/L; pH less than or
equal to 7.0; shock; Failure of standard supportive mea-
sures; decreased level of consciousness) were present.
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Instead, we preferred to be more aggressive with the use
of dialysis, prescribing SLED in every patient taking met-
formin with lactic acidosis (metabolic acidosis with an in-
creased anion gap and lactate concentration ≥ 5 mmol/L)
and AKI stage III.
The renal replacement therapy utilized in our protocol
was based on a bicarbonate buffer and intermittent
SLED to ensure adequate clearance of metformin. After
the first SLED and volume correction, a second session
was often needed (mean: 2.26 ± 2 treatments) to achieve
lactate ≤ 5 mmol/L. This is in agreement with the kinet-
ics of the drug, resulting in complete removal in about
48 h [33]. Very slow correction of potassium was critical
to avoid polarization abnormalities in conduction tis-
sues, especially in subjects whose K+ ≥ 7 mEq/L. The use
of these strategies led to an improvement in renal func-
tion within 3 days of admission, thus allowing patients
to be weaned from replacement therapy. Prolonged
hospitalization (mean: 10.6 ± 6.7 days) was often neces-
sary to complete the diagnostic and therapeutic plan and
to stabilize all clinical parameters, including control of
glycemia with the new insulin regimens. Unfortunately,
14.8% of patients did not regain their previous eGFR
values. No other deaths due to lactic acidosis were re-
ported a mean of 27.2 months after discontinuing met-
formin, and no new episodes of lactic acidosis were
observed. This is an indirect sign of the key role of met-
formin in the genesis of MALA.
Our study has several limitations. First, given the small
number of patients in our study, we did not find any
correlation between death and clinical or laboratory vari-
ables. Theoretically, comorbidities could influence this
outcome, but neither respiratory, cardiac, nor renal dis-
ease had a clear impact on outcome in this case series.
This suggests that MALA may be fatal independently
from comorbidities. Overall, there is very little informa-
tion available to predict the evolution of this condition
[21]. Second, we did not provide any control group to
demonstrate a significant improvement of survival in
MALA compared to other conditions characterized by
lactic acidosis.
Conclusions
In conclusion, we report a high incidence (in 2014, 32.9/
100,000 patient) but a relatively low mortality rate (21.4%)
of MALA. MALA tended to be precipited by AKI mainly
due to volume depletion. Importantly, patients had little
insight into how to manage their metformin dosing as
they continued their daily intake of the drug until toxic
levels were reached despite having conditions that
increased risk such as nausea and vomiting. SLED
hemodialysis and a very slow correction of the metabolic
profile was effective and led to satisfactory outcomes in
patients with MALA.
Additional files
Additional file 1: Table S1. Comorbidities and precipitating factors
associated with lactic acidosis (MALA). Death events are marked red.
(PPTX 47 kb)
Additional file 2: Figure S1. Incidence of MALA observed to our
Division between January 2000 and September 2014. It is indicated the
extensive educational campaign done by our Division for internal
medicine and metabolism specialists. (PPTX 105 kb)
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